JNJ-2113 long-term extension FRONTIER 2 study demonstrated sustained efficacy from Week 16 to Week 52 and safety results consistent with previously reported data (FRONTIER 1 Study) in a late-breaking oral presentation at the American Academy of Dermatology 2024 Annual Meeting   SAN DIEGO, March 10, 2024 /7Newswire — Johnson & Johnson today announced the first data …

Continue reading “New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year”

LOS ANGELES, March 10, 2024 /7Newswire — Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, today presented positive translational and Phase 1 clinical data demonstrating the company’s novel small molecule therapy PP405 reactivates dormant hair follicle stem cells to trigger hair growth. Data were presented in a late-breaking …

Continue reading “Pelage Presents Late-Breaking Data at AAD 2024 Meeting Demonstrating PP405 Activates Human Hair Follicle Stem Cells Ex Vivo and in Phase 1 Clinical Study”

THOUSAND OAKS, Calif., March 10, 2024 /7Newswire — Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will …

Continue reading “AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024”

ARLINGTON, Va., March 10, 2024 /7Newswire — The following is a statement from Ramsey Alwin, President and CEO of the National Council on Aging (NCOA), on yesterday’s passage of the federal appropriations package in the Senate: “We applaud Congress for funding critical assistance for low-income older Americans in today’s federal appropriations package. The $62.5 million bipartisan allocation for continued outreach …

Continue reading “Statement: Assistance on the Way for Low-Income Older Americans”

SCOTTSDALE, Ariz., March 9, 2024 /7Newswire — Bancorp 34, Inc. (OTCQB: BCTF), the parent company for Bank 34, reports consolidated fourth quarter of 2023 performance. Bancorp 34, Inc. (the “Company”) reported a net loss and diluted net loss per share, for the quarter ended December 31, 2023, of ($1.7 million) and ($0.40), respectively, compared to ($1.9 million) and ($0.81) for …

Continue reading “Bancorp 34, Inc. Reports 4th Quarter Performance, Provides Merger Update and Announces Proposed New Brand”